Guy's cancer cohort - real world evidence for cancer pathways
Open Access
- 17 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 20 (1), 1-6
- https://doi.org/10.1186/s12885-020-6667-0
Abstract
BackgroundThe burden of disease due to cancer remains substantial. Since the value of real-world evidence has also been recognised by regulatory agencies, we established a Research Ethics Committee (REC) approved research database for cancer patients (Reference: 18/NW/0297).Construction and contentGuy's Cancer Cohort introduces the concept of opt-out consent processes for research in a subset of oncology patients diagnosed and treated at a large NHS Trust in the UK. From April 2016 until March 2017, 1388 eligible patients visited Guy's and St Thomas' NHS Foundation Trust (GSTT) for breast cancer management. For urological cancers this number was 1757 and for lung cancer 677. The Cohort consists of a large repository of routinely collected clinical data recorded both retrospectively and prospectively. The database contains detailed clinical information collected at various timepoints across the treatment pathway inclusive of diagnostic data, and data on disease progression, recurrence and survival.ConclusionsGuy's Cancer Cohort provides a valuable infrastructure to answer a wide variety of research questions of a clinical, mechanistic, and supportive care nature. Clinical research using this database will result in improved patient safety and experience. Guy's Cancer Cohort promotes collaborative research and will accept applications for the release of anonymised datasets for research purposes.This publication has 21 references indexed in Scilit:
- Patients' perspectives on opt-out consent for observational research: systematic review and focus groupBritish Journal of Nursing, 2018
- Toward an MRI-based nomogram for the prediction of transperineal prostate biopsy outcome: A physician and patient decision toolUrologic Oncology, 2017
- Pathological Concordance between Prostate Biopsies and Radical Prostatectomy Using Transperineal Sector Mapping Biopsies: Validation and Comparison with Transrectal BiopsiesUrologia Internationalis, 2017
- Diagnostic value of MRI-based PSA density in predicting transperineal sector-guided prostate biopsy outcomesInternational Urology and Nephrology, 2017
- PD28-05 WORLDWIDE VARIATION IN DETERMINANTS FOR INCLUSION AND FOLLOW-UP IN ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER: RESULTS OF THE MOVEMBER FOUNDATION’S GLOBAL ACTION PLAN PROSTATE CANCER ACTIVE SURVEILLANCE (GAP3) INITIATIVEJournal of Urology, 2017
- Real World Evidence: A Quantitative and Qualitative Glance at Participant Feedback from a Free-Response Survey Investigating Experiences of a Structured Exercise Intervention for Men with Prostate CancerBioMed Research International, 2017
- Intraoperative Assessment of Tumor Resection Margins in Breast-Conserving Surgery Using 18F-FDG Cerenkov Luminescence Imaging: A First-in-Human Feasibility StudyJournal of Nuclear Medicine, 2016
- Laparoscopic radical prostatectomy outcome data: how should surgeon’s performance be reported? A retrospective learning curve analysis of two surgeonsecancermedicalscience, 2016
- Erratum: Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval timeBritish Journal of Cancer, 2016
- Are you now a good surgeon? T2 positive margin status as a quality outcome measure following radical prostatectomyWorld Journal of Urology, 2016